


WHAT IS CLAIMED IS:

1. An antibody that specifically binds to a Cav3 isoform or its $\delta 25$ splicing variants thereof.
- 5 2. The antibody of Claim 1, wherein the Cav3 isoform is a Cav3.2 isoform.
3. The antibody of Claim 1, wherein the antibody is a humanized antibody.
4. A pharmaceutical composition comprising an antibody of Claim 1 or
- 10 Claim 3 and a pharmaceutically acceptable carrier.
5. A method for diagnosing cancer comprising detecting the presence of a Cav3 isoform protein and/or its $\delta 25B$ splice variant in a tissue sample from a patient.
6. A method for treating cancer comprising detecting the presence of a
- 15 Cav3 isoform protein and/or its $\delta 25B$ splice variant in a patient according to Claim 5 and administering to the patient a therapeutically effective amount of an antibody against the Cav3 isoform and/or its $\delta 25B$.
7. A method for treating or control cancer comprising administering to a
- 20 patient in need thereof a therapeutically effective amount T type calcium channel selective inhibitor.
8. The method of Claim 7, wherein the T type calcium channel selective inhibitor is a tetrahydronaphthalene derivative of the formula



wherein R^1 is a halogen, R^2 is a lower-alkoxy-lower-alkyl-carbonyloxy, X is a C_2 - C_8 -alkylene, and A is a benzimidazolyl

optionally substituted at the N atom with 1 to 12 C atoms in the form of their free bases, their hydrates, or their pharmaceutically usable salts for the treatment, control, and prevention of cancer.

- 5
9. The method of Claim 7, wherein the T type calcium channel selective inhibitor is a mibefradil of the formula (1S,2S)-(2 {[3-(2-benzimidazolyl) propyl] methylamino} ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthylmethoxyacetate dihydrochloride.
- 10
10. A method of inhibiting cancer cell proliferation comprising administering to a patient in need thereof a therapeutically effective amount of mibefradil.
11. A method for inhibiting calcium entry into electrically non-excitable cells comprising administering a T type calcium channel selective inhibitor.
- 15
12. The method of Claim 11, wherein the electrically non-excitable cells are selected from the group consisting of lymphocytes, epithelial cells, connective tissue cells, secretory cells, Jurkat T-cells, MDA-468 cells and PC-3 cells.
- 20
13. A method of treating autoimmune diseases comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.
- 25
14. A method for preventing graft rejections comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.
15. A method for preventing apoptosis comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.